Hypothesis

Senescent c-Kit+ cardiac progenitor cells (CPCs) in the aged myocardium do not merely secrete a generic SASP; they actively release exosomes enriched in miR‑34a that suppress NAMPT expression in neighboring cardiomyocytes and fibroblast‑like cells, thereby lowering intracellular NAD+ levels. This NAD+ dampening creates a transiently hypometabolic state that limits excessive proliferation, reduces ROS‑driven DNA damage, and favors protective fibrosis over maladaptive remodeling. When senescent c-Kit+ CPCs accumulate beyond their useful coordination phase, chronic NAD+ depletion becomes deleterious, impairing the residual regenerative capacity of non‑senescent progenitors. Consequently, senolytic clearance restores NAD+ bioavailability, but if NAD+ synthesis is not simultaneously supported, the sudden NAD+ surge can hyperactivate PARP1 and SIRT1, exacerbating genomic instability and driving maladaptive hypertrophy.

Mechanistic Basis

1. Exosomal miR‑34a delivery – Senescent c-Kit+ CPCs express high levels of miR‑34a, a known suppressor of NAMPT, the rate‑limiting enzyme in the NAD+ salvage pathway [1]. Recent work shows that senescent cells load specific miRNAs into exosomes for paracrine transmission [2]; we hypothesize that miR‑34a‑rich exosomes are a core component of the c‑Kit+ CPC SASP.
2. NAD+‑mediated metabolic checkpoint – Reduced NAD+ diminishes PARP1 activity, decreasing consumption of NAD+ during DNA repair and lowering ROS generation. Simultaneously, low NAD+ favors HIF‑1α stabilization, promoting a glycolytic shift that supports fibroblast survival and collagen deposition without triggering excessive myocyte proliferation [3].
3. Threshold‑dependent outcome – Acute, transient NAD+ reduction after injury is protective, limiting energetic overload and preventing runaway hyperplasia. Persistent senescent cell presence drives NAD+ below a critical threshold, impairing the proliferative burst of residual c‑Kit− progenitors needed for myocardial regeneration [4].
4. Senolytic‑induced NAD+ rebound – Removal of senescent c-Kit+ CPCs exocytotically stops miR‑34a exosome release, allowing NAMPT rebound and NAD+ restoration. However, rapid NAD+ elevation can over‑activate PARP1 (consuming NAD+ in futile repair cycles) and SIRT1 (deacetylating PGC‑1α, leading to oxidative stress) if antioxidant defenses are not concurrently upregulated [5].

Predictions and Experimental Design

• Prediction 1: In aged mice undergoing myocardial infarction (MI), ischemic tissue will show elevated exosomal miR‑34a levels inversely correlated with cardiac NAD+ concentrations. Test: Isolate exosomes from infarct border zones, quantify miR‑34a by qPCR, and measure NAD+ via LC‑MS/MS; expect r < −0.6.
• Prediction 2: Senolytic treatment (e.g., dasatinib + quercetin) will decrease exosomal miR‑34a and raise NAD+ levels, but only when combined with an NAD+ precursor (NMN) will it reduce fibrosis and improve ejection fraction. Test: Four groups: (a) vehicle, (b) senolytic alone, (c) NMN alone, (d) senolytic + NMN. Assess fibrosis (Masson’s trichrome), NAD+ levels, and echocardiography at 28 days post‑MI.
• Prediction 3: Genetic inhibition of NAMPT in cardiomyocytes will phenocopy the protective effects of senescent c‑Kit+ CPCs, reducing ROS and fibrosis even in the presence of senolytic clearance. Test: Cross α‑MHC‑CreERT2; Nampt^fl/fl mice with MI model; compare to wild‑type senolytic-treated mice.

Potential Implications

If validated, this hypothesis reframes senescent c‑Kit+ CPCs not merely as “hostage negotiators” but as metabolic gatekeepers that tune tissue NAD+ to balance regeneration versus fibrosis. It suggests that senolytic strategies must be paired with metabolic adjuncts (e.g., NAD+ boosters) to avoid unleashing a NAD+‑driven maladaptive response, offering a combinatorial therapeutic avenue for age‑related heart failure.